m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00599)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
hsa-miR-193b
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | METTL3 modulates miR-193b mature process in an m6A-dependent manner. Reintroduction of hsa-miR-193b profoundly inhibits tumorigenesis of cervical cancer cells both in vivo and in vitro through CCND1 targeting. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Cervical cancer | ICD-11: 2C77 | ||
In-vitro Model | SiHa | Cervical squamous cell carcinoma | Homo sapiens | CVCL_0032 |
HeLa | Endocervical adenocarcinoma | Homo sapiens | CVCL_0030 | |
In-vivo Model | Mice were divided into two groups (n = 4/group) randomly. 3×106 cells suspended in 200 uL PBS were administered via subcutaneous injection over the right flank region of nude mice. After the development of palpable tumors (average volume, 50 mm3), intratumoral injection of synthetic miR-193b, or negative control complexed with siPORT Amine transfection reagent (Ambion, USA) was given 6 times at a 4-day interval. | |||
Cervical cancer [ICD-11: 2C77]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | METTL3 modulates miR-193b mature process in an m6A-dependent manner. Reintroduction of hsa-miR-193b profoundly inhibits tumorigenesis of cervical cancer cells both in vivo and in vitro through CCND1 targeting. | |||
Responsed Disease | Cervical cancer [ICD-11: 2C77] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
In-vitro Model | SiHa | Cervical squamous cell carcinoma | Homo sapiens | CVCL_0032 |
HeLa | Endocervical adenocarcinoma | Homo sapiens | CVCL_0030 | |
In-vivo Model | Mice were divided into two groups (n = 4/group) randomly. 3×106 cells suspended in 200 uL PBS were administered via subcutaneous injection over the right flank region of nude mice. After the development of palpable tumors (average volume, 50 mm3), intratumoral injection of synthetic miR-193b, or negative control complexed with siPORT Amine transfection reagent (Ambion, USA) was given 6 times at a 4-day interval. | |||